Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial by Mohammad Bosaeed, MD, Hanan H Balkhy, ProfMD, Sultan Almaziad, MD, Haya A Aljami, BSc, Hind Alhatmi, MD, Hala Alanazi, BSN, Mashael Alahmadi, BSc, Ayah Jawhary, MD, Mohammed W Alenazi, BSc, Abdulrahman Almasoud, BSc, Rawan Alanazi, PharmD, Mustapha Bittaye, PhD, Jeremy Aboagye, MSc, Nahla Albaalharith, BSN, Sarah Batawi, MD, Pedro Folegatti, MSc, Fernando Ramos Lopez, MSc, Katie Ewer, PhD, Khalid Almoaikel, PhD, Majed Aljeraisy, PharmD, Adel Alothman, MD, Sarah C Gilbert, ProfPhD, Naif Khalaf Alharbi, PhD

Get full text